[1] JORGENSEN R. Altered gene expression in plants due to transinteractions between homologous genes[J]. Trends Biotechnol, 1990, 8(12):340-344.
[2] FIRE A, XU S, MONTGOMERY M K,et al. Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans[J]. Nature, 1998, 391(6669):806-811.
[3] ELBASHIR S M, HARBORTH J, LENDECKEL W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells[J]. Nature, 2001,411(6836):494-498.
[4] NAITO Y, UI-TEI K. Designing functional siRNA with reduced off-target effects[J]. Methods Mol Biol, 2013,942: 57-68.
[5] SNØVE J O, HOLEN T. Many commonly used siRNAs risk off-target activity[J]. Biochem Biophys Res Commun, 2004, 319(1):256-263.
[6] DOKKA S, TOLEDO D, SHI X, et al. Oxygen radical mediated pulmonary toxicity induced by some cationic liposomes[J]. Pharm Res, 2000, 17(5):521-525.
[7] WANG J, LU Z, WIENTJES M G, et al. Delivery of siRNA therapeutics: barriers and carriers[J]. AAPS J, 2010, 12(4):492-503.
[8] SIOUD M. Does the understanding of immune activation by RNA predict the design of safe siRNAs?[J]. Front Biosci, 2008, 13: 4379-4392.
[9] WU S Y, YANG X, GHARPURE K M, et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity[J]. Nat Commun, 2014, 5:3459.
[10] OZPOLAT B, SOOD A K, LOPEZ-BERESTEIN G. Liposomal siRNA nanocarriers for cancer therapy[J]. Adv Drug Deliv Rev, 2014, 66:110-116.
[11] KLEINMAN M E, YAMADA K, TAKEDA A, et al. Sequence-and target-independent angiogensis suppression by siRNA via TLR3[J]. Nature, 2008, 452(7187):591-597.
[12] ALNYLAM. Complete Results of our ALN-RSV01 Phase IIb Study[EB/OL]. [2012-09-04]. http://www.alnylam.com/capella/presentations/complete-results-of-our-aln-rsv01-phase-iib-study/
[13] LEACHMAN S A, HICKERSON R P, SCHWARTZ M E, et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder[J]. Mol Ther, 2010, 18(2):442-446.
[14] SYLENTIS. Sylentis announces top-line results from Phase II study SYLTAG for RNAi drug bamosiran(SYL040012) in Glaucoma[EB/OL]. [2015-10-02]. http://www.sylentis.com/index.php/en/news/professional-news/103-sylentis-announces-top-line-results-from-phase-ii-study-syltag-for-rnai-drug-bamosiran-syl040012-in-glaucoma.
[15] SYLENTIS. Sylentis reports positive Phase Ⅱ results with SYL1001 in treating ocular pain related to dry eye syndrome[EB/OL]. [2016-03-14]. http://www.sylentis.com/index.php/en/news/professional-news/108-sylentis-reports-positive-phase-ii-results-with-syl1001-in-treating-ocular-pain-related-to-dry-eye-syndrome.
[16] QUARK.Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant[EB/OL]. [2016-07-28]. http://quarkpharma.com/?p=12340.
[17] RIBO.The first clinical study of small necleicacid was approved in China [EB/OL]. [2015-12-25]. http://www.ribolia.com/cn/news/detail.aspx?NewsId=179&BasicClassId=509&HeadID=3.
[18] SILENSEED. Pancreatic Cancer[EB/OL]. [2017-10-22]. http://silenseed.com/?page_id=2539.
[19] BURNETT J C, ROSSI J J. RNA-based therapeutics: current progress and future prospects[J]. Chem Biol, 2012, 19(1):60-71.
[20] QUARK. Quark Pharmaceuticals Doses First Patients in Two Pivotal Phase III Studies and One Phase II Study of RNAi-Based Therapeutics for Kidney and Eye Indications[EB/OL]. [2016-3-14]. http://quarkpharma.com/?p=12305.
[21] ZUCKERMAN J E, GRITLI I, TOLCHER A, et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA[J]. Proc Natl Acad Sci USA, 2014, 111(31):11449-11454.
[22] ARBUTUS. Arbutus Reports Topline Results from TKM-PLK1 HCC Clinical Trial[EB/OL]. [2016-7-19]. http://investor.arbutusbio.com/releasedetail.cfm?ReleaseID=980210.
[23] ALNYLAM. Complete Study Results from our ALN-VSP Phase I Trial and Extension Study Published in “Cancer Discovery”[EB/OL]. [2013-1-30]. http://www.alnylam.com/capella/publications/complete-study-results-from-our-aln-vsp-phase-i-trial-and-extension-study-published-in-cancer-discovery/.
[24] MEDICINES. The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran[EB/OL]. [2017-3-17]. http://www.themedicinescompany.com/investors/news/medicines-company-and-alnylam-pharmaceuticals-report-positive-final-results-orion-1.
[25] LIDDELL A M, DAVEY RT J R, MEHTA A K, et al. Characteristics and clinical management of a cluster of 3 patients with ebola virus disease, including the first domestically acquired cases in the United States[J]. Ann Intern Med, 2015,163(2):81-90.
[26] KRAFT C S, HEWLETT A L, KOEPSELL S, et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States[J]. Clin Infect Dis, 2015, 61(4):496-502.
[27] ALNYLAM. Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR(hATTR) Amyloidosis Patients with Polyneuropathy. [EB/OL]. [2017-9-20]. http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1041081.
[28] DICERNA. Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1(PH1) [EB/OL]. [2016-3-13]. http://investors.dicerna.com/releasedetail.cfm?ReleaseID=970877.
[29] SILENCE.Atu027 update[EB/OL]. [2016-4-5]. http://www.silence-therapeutics.com/news-media/#page=3.
[30] OZCAN G, OZPOLAT B, COLEMAN R L, et al. Preclinical and clinical development of siRNA-based therapeutics[J]. Adv Drug Deliv Rev, 2015, 87: 108-119.
[31] TRIOZZI P, KOOSHKI M, ALISTAR A, et al. Phase I clinical trial of adoptive cellular immunotherapy with APN401 in patients with solid tumors[J]. J Immunother Cancer, 2015, 3(2):175.
[32] FIERCEBIOTECH.Alnylam plunges after deaths force it to pull PhIII blockbuster candidate revusiran[EB/OL]. [2016-10-6]. http://www.fiercebiotech.com/biotech/alnylam-plunges-after-deaths-sees-it-pull-phiii-blockbuster-candidate-revusiran.
[33] ALNYLAM. Pre-Clinical Data and Advancement of ALN-TTRsc02 for Transthyretin-Mediated Amyloidosis[EB/OL]. [2015-10-14]. http://www.alnylam.com/capella/presentations/pre-clinical-data-and-advancement-of-aln-ttrsc02/.
[34] ALNYLAM. New Exploratory Analysis Results from Fitusiran, an Investigational RNAi Therapeutic for the Treatment of Hemophilia and Rare Bleeding Disorders[EB/OL]. [2017-2-2]. http://www.alnylam.com/capella/presentations/new-exploratory-analysis-fitusiran/.
[35] ALNYLAM. Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria(PNH)[EB/OL]. [2016-12-05]. http://www.alnylam.com/capella/presentations/aln-cc5-phase-1-2-data-ash-2016/.
[36] ALNYLAM. Updated Results from Phase 1/2 Study of ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria(PNH)[EB/OL]. [2016-12-05]. http://www.alnylam.com/capella/presentations/aln-cc5-phase-1-2-data-ash-2016/.
[37] ALNYLAM. Clinical Data from ALN-AAT and Non-Clinical Research Demonstrating Continued RNAi Platform Optimization and Leadership in the Field[EB/OL]. [2016-09-28]. http://www.alnylam.com/capella/presentations/aln-aat-data-and-rnai-platform-optimization/.
[38] ALNYLAM. Initial Results from Ongoing Phase 1/2 Study with ALN-GO1, in Development for the Treatment of Primary Hyperoxaluria Type 1[EB/OL]. [2016-09-24]. http://www.alnylam.com/capella/presentations/initial-clinical-results-from-aln-go1-for-ph1/.
[39] SIRNAOMICS. Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705, for Treatment of Hypertrophic Scar[EB/OL]. [2017-02-06]. http://sirnaomics.hz.17uhui.com.cn/page64?article_id=490.
[40] SIRNAOMICS. BioWorld Today Reports Sirnaomics' Filing of First siRNA IND in China[EB/OL]. [2016-01-20]. http://sirnaomics.hz.17uhui.com.cn/page64?article_id=392.
[41] CLINICALTRIALS.GOV.MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT(PSCT19)[EB/OL]. [2016-03-22]. https://clinicaltrials.gov/ct2/show/NCT02528682?term=siRNA& rank=25.